Literature DB >> 15375558

Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors.

Silvia G Isler1, Christian U Ludwig, Ruth Chiquet-Ehrismann, Susanne Schenk.   

Abstract

SPARCL1 mRNA was shown to be downregulated in NSCLC as well as in prostate, colon, and bladder carcinomas. Therefore, SPARCL1 was suggested to be a tumor suppressor gene. By microsatellite analysis, real-time quantitative PCR, and sequence analysis of all exons including the intron-exon junctions and a part of the putative promoter region, we could not find any deletion or mutation that might be responsible for the downregulation of SPARCL1 in NSCLC. We conclude that SPARCL1 is therefore not a classical tumor suppressor gene with a deletion or mutation in one allele and another mutation in the second allele. To test whether SPARCL1 could be downregulated by repression of transcription we performed luciferase reporter gene assays with 10 different SPARCL1 promoter constructs. These experiments revealed that the presence of exon 1 is able to cause a reduction in luciferase activity. Furthermore, we show that the inhibitory activity of exon 1 can be transferred to a heterologous promoter. This indicates that SPARCL1 downregulation might be mediated (at least in part) through transacting factors that bind to exon 1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375558

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

2.  SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer.

Authors:  Hong Zhang; Emma Widegren; Da-Wei Wang; Xiao-Feng Sun
Journal:  Tumour Biol       Date:  2011-09-02

Review 3.  Microenvironment of the involuting mammary gland mediates mammary cancer progression.

Authors:  Pepper Schedin; Jenean O'Brien; Michael Rudolph; Torsten Stein; Virginia Borges
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

4.  An initial characterization of the serum phosphoproteome.

Authors:  Weidong Zhou; Mark M Ross; Alessandra Tessitore; David Ornstein; Amy Vanmeter; Lance A Liotta; Emanuel F Petricoin
Journal:  J Proteome Res       Date:  2009-12       Impact factor: 4.466

5.  Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.

Authors:  Ting Li; Xia Liu; Antai Yang; Wenjie Fu; Fuqiang Yin; Xiaoyun Zeng
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

6.  Prognostic value of SPARCL1 in patients with colorectal cancer.

Authors:  Wei Han; Fang Cao; Wei Ding; Xiao-Jiao Gao; Fang Chen; Yong-Wei Hu; Hou-Zhong Ding
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

7.  Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.

Authors:  Chaoyong Shen; Yuan Yin; Huijiao Chen; Ruixue Wang; Xiaonan Yin; Zhaolun Cai; Bo Zhang; Zhixin Chen; Zongguang Zhou
Journal:  BMC Gastroenterol       Date:  2018-07-04       Impact factor: 3.067

8.  Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer.

Authors:  Federico Pio Fabrizio; Angelo Sparaneo; Andrea Fontana; Tommaso Mazza; Paolo Graziano; Angela Pantalone; Paola Parente; Flavia Centra; Natalizia Orlando; Domenico Trombetta; Annamaria la Torre; Gian Maria Ferretti; Marco Taurchini; Concetta Martina Di Micco; Evaristo Maiello; Vito Michele Fazio; Antonio Rossi; Lucia Anna Muscarella
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

9.  SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.

Authors:  Qing Nian; Qing Xiao; Li Wang; Jing Luo; Li-Ping Chen; Ze-Song Yang; Lin Liu
Journal:  Int J Mol Med       Date:  2014-02-07       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.